Keybanc Maintains Overweight on HCA Healthcare, Lowers Price Target to $420
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Matthew Gillmor maintains an Overweight rating on HCA Healthcare but lowers the price target from $475 to $420.
October 28, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Keybanc analyst Matthew Gillmor maintains an Overweight rating on HCA Healthcare but lowers the price target from $475 to $420.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in valuation. This mixed signal may result in a neutral short-term impact on HCA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100